Lymphopenia as an indication for the use of recombinant interleukin-2-Reference-Cited by-同舟云学术

Lymphopenia as an indication for the use of recombinant interleukin-2

Published:2020-07-10 Issue:8 Volume: Page:32-54
ISSN:2075-0277
Container-title:Terapevt (General Physician)
language:ru
Short-container-title:

Author:

Egorova V. N.¹,Babachenko I. V.²^ORCID,Gisinger O. A.³^ORCID,Titov K. S.³

Affiliation:

1. «BIOTECH» LLC., Saint Petersburg, Russia

2. Children’s research and clinical center for infectious diseases of Russia’s Federal Medico- Biological Agency, Saint Petersburg, Russia

3. Federal State Autonomous Educational Institution of Higher Education Peoples’ Friendship University of Russia, Moscow, Russia

Abstract

Pathogenetic aspects of lymphopenia in various pathological conditions are studied. A statistical assessment of the incidence of lymphopenia in the world is given. It is shown that prolonged lymphopenia increases the risk of developing diseases of infectious genesis and an adverse outcome. A long-existing decrease in lymphocytes leads to the activation of opportunistic infections and becomes the basis for the development of malignant neoplasms and autoimmune pathology. Recombinant interleukin 2 (Roncoleukin®), filling the deficiency of endogenous interleukin 2, is a means of not only substitution, but also of inductive therapy. Restoring the regulatory effects of interleukin 2, Roncoleukin® levels the manifestations of lymphopenia and positively affects the dynamics and outcome of the disease.

Publisher

PANORAMA Publishing House

Reference63 articles.

1. Avakimyan S. V. Ronkoleikin v korrektsii immunnoi nedostatochnosti u bolntkh s ostrym destruktivnym pankreatitom [Roncoleukinum in the Improvement of Immunodefi ciency in the Patients with Acute Destructive Pancreatitis]. Kuban Scientifi c Medical Bulletin. 2010: 9 (123); 11–13.

2. Avakimyan S. V. Narusheniye immunnogo statusa pri ostrom pankreatite i ego korrektsiya [Malformation of Immune Status in Acute Pancreatitis and Its Improvement]. Surgery Bulletin of I. I. Grekov. 2015: 174 (1); 16–19.

3. Anisimov A. Yu. Immunoterapiya Ronkoleikinom® v kompleksnom lechenii bolnykh abdominalnym sepsisom: posobiye dlya vrachei [Immune Therapy Using Roncoleukinum® in a Comprehensive Treatment of Patients with Abdominal Sepsis: Guide for Doctors]. 2004; 28.

4. Ashitkova N. V. Diagnosticheskoye i prognosticheskoye znacheniye limfopenicheskikh sostouaniy u novorozhdennykh detei s oslozhnennym techeniyem neonatalnogo perioda [Diagnostic and Prognostic Value of Lymphopenic Ailments in Newborn Infants with Complicated Neonatal Period]. Pediatrics. 2009: 87 (1); 49–54.

5. Ashitkova N. V. Eff ektivnost preparata rekombinantnogo interleikina-2 cheloveka v terapii neonatalnogo sepsisa i tyazhelykh neonatalnykh infektsiy [Eff ecacy of Recombinant Human Interleukin-2 in the Treatment of Neonatal Sepsis and Severe Neonatal Infections]. Pediatrics. 2009: 87 (3); 80–86.

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. D-dimer: issues of laboratory diagnostics;Terapevt (General Physician);2023-06-21

2. Use of recombinant interleukin-2 in traumatic disease in veterinary medicine;RUDN Journal of Agronomy and Animal Industries;2022-06-16

3. Ronkoleikin, Vladonix and interferon alpha-2b in the treatment of coronavirus infection in outpatient practice;Terapevt (General Physician);2022-03-29

4. Recombinant cytokines in the practice of the therapist;Terapevt (General Physician);2021-05-19